Ocugen (MEX:OCGN) Tax Provision : MXN0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ocugen Tax Provision?

Ocugen's tax provision for the three months ended in Dec. 2024 was MXN0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was MXN0.00 Mil.

Ocugen Tax Provision Historical Data

The historical data trend for Ocugen's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Tax Provision Chart

Ocugen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Provision

Get a 7-Day Free Trial

1.07

Ocugen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Ocugen Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00 Mil.

Ocugen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (MEX:OCGN) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

OCGN:USA 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").